Elite Pharmaceuticals

We are dedicated to developing and manufacturing generic prescription drugs in a variety of therapeutic categories in tablet, capsule and powder forms. EPIC develops, manufactures and markets a broad array of generic pharmaceuticals that are improving the quality of life of people around the world. We encourage you to explore our product catalog to learn more about our products, or visit one of our individual product pages. EPIC operates a 110,000 square foot facility with approximately 200 employees. Our facility is a fully functional FDA approved manufacturing facility. We have the ability to manufacture a diverse portfolio of products including CII - CV controlled products. In addition to internal drug development and manufacture, we also offer contract manufacturing services with an emphasis on quality, customer satisfaction and low cost. We have a proven track record as we are the largest contract manufacturer in the United States for a large pharmaceutical company.

Known pioneer of specialty products with commercial team expertise, positioned for product partnerships and additional opportunities. Generic drug provider focused on development, sourcing, and commercialization of high-quality brand alternatives. Experienced manufacturer offering a full range of customizable contract services to meet individual needs.

We are able to leverage our long-standing relationships across complex and highly regulated markets resulting in transparent and mutually beneficial relationships. We are experts in the sourcing, development, manufacturing and marketing of prescription generic and branded pharmaceuticals, selective biosimilar products, as well as over-the-counter (OTC) and consumer health products. The organisation was established by a team of highly experienced and well-recognised industry-leading experts. Our products are currently registered and being commercialised in the United Kingdom and certain European markets, as well as Australia, New Zealand, and in various Asia Pacific countries such as Singapore, Philippines and Malaysia. The Edge Pharmaceutical Group is a privately owned global pharmaceutical company, centred around strategic affiliations in key markets and with a strong heritage in the development, manufacturing, registration, and supply of healthcare products. We offer our business partners a unique market access service covering various cross-market technical requirements, regulatory compliance, and commercial support to ensure all facilities, operations, and products comply with complex individual market needs. To continue building strong, sustainable and strategic global partnerships from which to supply our product range. To provide the most reliable and personal support to all our customers, with the objective to consistently supply extremely cost-effective and high-quality healthcare products globally.

Our products have effectively met the medical needs of patients worldwide, with Lidoderm (a non-opioid 5% Lidocaine Patch) playing a significant role in alleviating the suffering of individuals living with pain associated with Post Herpetic Neuralgia, but our teams are continuing to develop innovative products to address unmet needs in the market. We develop innovative products in several therapeutic areas, including pain management, CNS disorders, and dermatology, using our proprietary and innovative drug delivery technologies. As a California-based pharmaceutical company, we are known for developing and manufacturing complex formulations entirely in-house that are difficult to replicate. Teikoku Pharma USA (TPU), a subsidiary of Teikoku Seiyaku, Japan, is a family-owned, privately-held international specialty pharmaceutical company founded in 1997 in California. Our team, includes experts in R&D, clinical, regulatory, and manufacturing. Catlep, Japan’s first transdermal indomethacin plaster for prescription use, is approved and production begins. Seltouch®, a transdermal felbinac plaster for prescription use, is approved in Japan and production begins. Teikoku Seiyaku is a world leader in the research, development, manufacture, and commercialization of pharmaceutical drugs.

Exela® targets the development and manufacturing of generic and proprietary sterile injectable products with high barriers to market entry, via an Abbreviated New Drug Approval or 505(b)(2) regulatory pathway. We develop products that enhance the patient or provider experience such as easing the burden of administration, providing an improved safety profile, faster drug preparation, or reduce drug waste. In other words, we strive to improve patient outcomes while reducing overall health care costs. Legal and Privacy PolicyCCPA PolicyReturn Goods PolicyTransparency in Coverage MRF | Blue Cross NC.

We are equipped to develop high-quality and affordable generics, as well as innovative products for unmet medical and patient needs. We are driven to establish partnerships with companies interested in exploring aerosol-based technologies for generic molecules or new chemical entities. Our vision is to become a leading pharmaceutical company, a preeminent force in the field of innovative pharmaceutical development that consistently delivers cutting-edge products acclaimed for their therapeutic contributions around the globe. We are driven to meet the needs of both patients and our stakeholders by developing innovative and cost-effective products. We are committed to developing new products that deliver improved therapeutic outcomes, while meeting unmet patient needs. We are an emerging specialty pharmaceutical company based out of New Jersey, United States. We are a research, development, and commercialization enterprise specializing in aerosol-based drug-delivery products for nasal, inhalation, eye, and oral applications. We are pleased to bring to you our latest technologies, and their wide-reaching potential benefits for our patients.